Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Coca-Cola reports Q4 beat, Elliott discloses Phillips 66 stake: Morning Buzz
- Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
- Vertex Pharmaceuticals price target raised to $520 from $460 at Truist
- Vertex Pharmaceuticals price target raised to $407 from $402 at RBC Capital
- Vertex Pharmaceuticals’ Journavx: Strategic Market Adoption and Growth Outlook